Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

Subcutaneous injection-site reactions vs. infection red flags

How mild skin reactions differ from infection, contamination and allergic emergencies, and when to get urgent care

Evidence verdict: Based on FDA labels, infectious-disease and allergy guidelines, and outbreak reports. It describes warning signs; it does not tell anyone how to inject or treat themselves. [1, 4, 5]

Last reviewed: Oct 27, 2026

In 30 seconds

• Mild redness, itching, bruising or a small bump where a needle went in are the most common reactions to approved injectable peptides, and they are usually short-lived. [1, 2] [Regulatory, Observational]
• Repeatedly injecting the same spot can cause lipohypertrophy, a rubbery lump of fatty tissue. In insulin users it was strongly linked to not rotating sites and to reusing needles. [3] [Observational]
• Spreading redness, warmth, increasing pain, pus, fever or red streaks suggest infection (cellulitis or abscess) and need prompt medical care. [4] [Guidance]
• Trouble breathing, throat or tongue swelling, widespread hives, faintness or collapse within minutes to hours can be anaphylaxis, a medical emergency. Call emergency services. [5, 6] [Guidance, Regulatory]

Common local reactions

In approved peptide drugs, local reactions are listed side effects. The Zepbound label lists injection-site reactions among adverse reactions reported in at least 5% of patients. [1] [Regulatory] A 2026 review of FDA adverse-event reports for GLP-1 drugs found skin and injection-site reactions were the third most frequently reported category. Common reactions were pain, bleeding, redness, bruising, a lump, itching and swelling, and most were mild to moderate. [2] [Observational] Why a given reaction happens (for example, an excipient, a preservative or the peptide itself) is usually not established for unapproved products. UNVERIFIED

Lipohypertrophy

Lipohypertrophy is a thickened, rubbery swelling under the skin at an overused injection site. In 430 insulin-injecting adults, nearly two-thirds had it. Correct site rotation was the strongest protective factor, and risk rose with needle reuse. People with lipohypertrophy also had more unexplained low blood sugar and glucose swings, consistent with erratic absorption from the affected tissue. [3] [Observational] Whether the same pattern applies to other injected peptides has not been studied. UNVERIFIED

Infection red flags

IDSA guidelines describe cellulitis as spreading redness, warmth and tenderness of the skin, and abscesses as collections of pus. Abscesses generally need to be drained by a clinician, and systemic signs such as fever or a fast heart rate point to more serious infection. [4] [Guidance] A lump that is warm, growing, painful, draining, or accompanied by fever should be seen promptly. A sterile (non-infected) lump and an infected one can look alike, and only a clinician can tell them apart, sometimes with culture. [4] [Guidance] Unusual organisms happen. The largest US outbreak of Mycobacterium abscessus abscesses, 87 people, was traced to an unlicensed injectable sold in alternative-medicine circles. Such infections may not respond to routine antibiotics, so tell the clinician exactly what was injected. [7] [Observational]

Endotoxin and contamination

Endotoxin (bacterial lipopolysaccharide) causes fever and inflammation, and ordinary preservatives do not destroy it. Injectable drugs are tested for it with the USP <85> method. [8] [Regulatory] Test purchases of semaglutide sold online without a prescription found endotoxin in every sample. [9] [Observational] Commercial-grade synthetic peptides used in research have also tested positive. [10] [Lab] Fever, chills or feeling acutely unwell within hours of an injection can come from endotoxin or from bacterial contamination. Either one needs medical assessment. UNVERIFIED for any specific product. Contaminated injectables in health-care settings have caused bloodstream infections with substantial death rates. [11] [Observational]

Allergic reactions and anaphylaxis

Approved peptide labels warn about serious hypersensitivity. The Wegovy label reports anaphylaxis and angioedema and tells patients to stop the drug and seek care if they occur. [6] [Regulatory] The World Allergy Organization defines anaphylaxis as a severe, potentially life-threatening systemic reaction. It typically involves skin or mucosal symptoms together with breathing difficulty, low blood pressure or gut symptoms, and epinephrine is the first-line treatment. [5] [Guidance] If these signs appear, call emergency services. Do not wait to see whether the reaction settles.

Why the product matters

With an approved drug, the label lists the excipients and the expected reactions, and there is a manufacturer to report problems to. With an unapproved vial, sterility, endotoxin level and contents are unknown, which makes it harder for a clinician to judge what is going on. [9, 12] [Observational, Policy] Bring the vial and its packaging to any medical visit. This page gives no injection technique, preparation or treatment instructions.

Evidence levels used on this page

• [Regulatory] FDA, USP or WADA primary document or an FDA-approved label. [Controlled study] randomized trial or systematic review of trials. [Observational] surveillance, pharmacovigilance or cohort data. [Lab] analytical, cell or animal work. [Guidance] professional-society guidance. [Policy] Open Peptide Project published policy.

Related

Bacteriostatic water and sterility risks, Endotoxins and TFA salts, Immunogenicity and anti-drug antibodies

References

1. ZEPBOUND (tirzepatide) prescribing information, Eli Lilly (NDA 217806). DailyMed/openFDA setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective Aug 28, 2026.
2. Elgindi et al. Glucagon-like peptide-1 receptor agonist-associated injection site and dermatologic reactions. Clin Dermatol. 2026. PMID 42692277.
3. Blanco M, et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013. PMID 23886784.
4. Stevens DL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014. PMID 24973422.
5. Cardona V, et al. World Allergy Organization anaphylaxis guidance 2020. World Allergy Organ J. 2020. PMID 33204386.
6. WEGOVY (semaglutide) injection and tablets, prescribing information, Novo Nordisk (NDA 215256). DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, published Jun 30, 2026.
7. Galil K, et al. Abscesses due to Mycobacterium abscessus linked to injection of unapproved alternative medication. Emerg Infect Dis. 1999. PMID 10511524.
8. United States Pharmacopeia. General Chapter <85> Bacterial Endotoxins Test. https://www.usp.org/harmonization-standards/pdg/general-methods/bacterial-endotoxins (usp.org returned HTTP 403 to our checker; Caution URL UNVERIFIED this run)
9. Ashraf AR, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res. 2024. PMID 39509151.
10. Weinstein JR, et al. Lipopolysaccharide is a frequent and significant contaminant in microglia-activating factors. Glia. 2008. PMID 17910052.
11. Nyandwaro K, et al. Healthcare-associated bloodstream infections caused by contamination of intravenous fluids and medicines in LMIC facilities: a scoping review. Antimicrob Resist Infect Control. 2025. PMID 40156049.
12. Open Peptide Project. Testing standard (Open Peptide Standard, Protocol v1.1), read Oct 27, 2026. https://openpeptideproject.org/standard/

Disclaimer: This page is for education only. It is not medical advice, and it does not endorse using, buying or preparing any unapproved product. Talk to a licensed clinician before you start, stop or change any treatment.